Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuankai Shi

Showing results (241-250 of 347) with videos related to

Pageof 35
Sort By:
Cancer Immunology, Immunotherapy : CII|May 24, 2025
Clinical, immune cell, and genetic features predicting survival and long-term response to first-line chemo-immunotherapy treatment for non-small cell lung cancerLiling Huang, Haohua Zhu, Liyuan Dai, et al.
Genomics, Proteomics & Bioinformatics|December 11, 2024
A Novel IgG-IgM Autoantibody Panel Enhances Detection of Early-stage Lung Adenocarcinoma from Benign NodulesRongrong Luo, Xiying Li, Ruyun Gao, et al.
Cancer Medicine|February 18, 2020
Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trialYing Cheng, Baohui Han, Kai Li, et al.
Experimental Hematology & Oncology|June 12, 2024
Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I studyYuankai Shi, Xiaohong Han, Qian Zhao, et al.
Journal of Translational Medicine|September 21, 2021
Low CCL19 expression is associated with adverse clinical outcomes for follicular lymphoma patients treated with chemoimmunotherapyYu Zhou, Shasha Wang, Yunxia Tao, et al.
Signal Transduction and Targeted Therapy|December 1, 2025
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinibYuankai Shi, Dongqing Lv, Weineng Feng, et al.
BMC Medicine|January 8, 2023
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa studyYuankai Shi, Jianying Zhou, Yanqiu Zhao, et al.
Plos One|January 10, 2014
The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapyNing-Ning Zhang, Yu-Tao Liu, Li Ma, et al.
Molecular & Cellular Proteomics : MCP|March 21, 2024
High-Throughput Antigen Microarray Identifies Longitudinal Prognostic Autoantibody for Chemoimmunotherapy in Advanced Non-Small Cell Lung CancerLiyuan Dai, Qiaoyun Tan, Lin Li, et al.
Head & Neck|April 9, 2014
Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trialYe Guo, Mei Shi, Ankui Yang, et al.
Pageof 35

Showing results (241-250 of 347) with videos related to

Sort By:
Pageof 35
Cancer Immunology, Immunotherapy : CII|May 24, 2025
Clinical, immune cell, and genetic features predicting survival and long-term response to first-line chemo-immunotherapy treatment for non-small cell lung cancerLiling Huang, Haohua Zhu, Liyuan Dai, et al.
Genomics, Proteomics & Bioinformatics|December 11, 2024
A Novel IgG-IgM Autoantibody Panel Enhances Detection of Early-stage Lung Adenocarcinoma from Benign NodulesRongrong Luo, Xiying Li, Ruyun Gao, et al.
Cancer Medicine|February 18, 2020
Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trialYing Cheng, Baohui Han, Kai Li, et al.
Experimental Hematology & Oncology|June 12, 2024
Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I studyYuankai Shi, Xiaohong Han, Qian Zhao, et al.
Journal of Translational Medicine|September 21, 2021
Low CCL19 expression is associated with adverse clinical outcomes for follicular lymphoma patients treated with chemoimmunotherapyYu Zhou, Shasha Wang, Yunxia Tao, et al.
Signal Transduction and Targeted Therapy|December 1, 2025
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinibYuankai Shi, Dongqing Lv, Weineng Feng, et al.
BMC Medicine|January 8, 2023
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa studyYuankai Shi, Jianying Zhou, Yanqiu Zhao, et al.
Plos One|January 10, 2014
The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapyNing-Ning Zhang, Yu-Tao Liu, Li Ma, et al.
Molecular & Cellular Proteomics : MCP|March 21, 2024
High-Throughput Antigen Microarray Identifies Longitudinal Prognostic Autoantibody for Chemoimmunotherapy in Advanced Non-Small Cell Lung CancerLiyuan Dai, Qiaoyun Tan, Lin Li, et al.
Head & Neck|April 9, 2014
Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trialYe Guo, Mei Shi, Ankui Yang, et al.
Pageof 35